KRAS and cancer: In these cancers, MYCN is a bona fide oncogenic driver (Burkhart et al., 2003, Weiss et al., 1997) and, similar to KRAS in KRAS-driven tumors, preclinical inhibition of MYCN protein leads to tumor growth inhibition in neuroblastoma mouse models (Brockmann et al., 2013, Burkhart et al., 2003, Delehouze et al., 2014, Faisal et al., 2011, Gustafson et al., 2014, Puissant et al., 2013).